Phase-3 drug trial for refractory rheumatoid arthritis succeeds

A new drug appears to help people who suffer from rheumatoid arthritis, but eventually stop benefitting from the use of the current top treatment: injectable, bioengineered proteins that interfere with the action of a powerful inflammatory substance.

Leave a Reply

Your email address will not be published. Required fields are marked *